** Shares of Immunome Inc IMNM.O down 10% to $8.42 before the bell after overnight follow-on priced

** Bothell, Washington-based oncology specialist late Weds announced ~19.3 mln shares at $7.75 for $150 mln gross raise

** Deal size boosted from $125 mln, priced at 17.1% discount to last sale

** JP Morgan, TD Cowen, Leerink and Guggenheim jt bookrunners

** Co plans to use net offering proceeds to fund clinical/preclinical development of pipeline assets, and general purposes, per the SEC filing

** With ~62.42 mln shares outstanding, IMNM has ~$584 mln market cap, per LSEG data

** Through Weds close, stock down 12% YTD and down ~50% over the past 12 months

** Still, all 7 analysts covering IMNM are bullish, including 4 "strong buy" ratings with median PT of $31.50 - LSEG

(Lance Tupper is a Reuters market analyst. The views expressed are his own)

((lance.tupper@tr.com 1-646-279-6380))